Latest bladder cancer Stories
The Rottenstein Law Group, which represents clients with injuries allegedly caused by prescription drugs including Actos, has learned of more evidence suggesting a link between Actos and bladder cancer. New York, NY (PRWEB) July 03, 2012 The Rottenstein Law Group, which represents clients who claim they suffered harm as a result of having taken the type 2 diabetes drug Actos, is publicizing yet another study suggesting that Actos might cause bladder cancer. At the University of Alberta...
The Actos Resource Center is the Web’s largest source for information on Actos warnings, research, side effects and legal news. Visit http://www.ActosLawsuitUpdate.com Orlando, FL (PRWEB) July 03, 2012 The Actos Bladder Cancer Center is alerting patients who have taken the drug Actos for their diabetes that researchers have identified an explanation for the drug’s link to bladder cancer. Legal help is still available for those just discovering they have been affected. Anyone who has...
Parker Waichman LLP has filed a lawsuit on behalf of a Virginia man who developed bladder cancer after taking Takeda’s diabetes drug, Actos (pioglitazone). The lawsuit points out the fact that the Defendants have yet to alert their customers to the increased risk of bladder cancer associated with using the medication for one year. (PRWEB) June 26, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed lawsuit on...
Parker Waichman LLP has filed a lawsuit alleging that Takeda’s diabetes drug Actos (pioglitazone) caused bladder cancer. The suit claims that the Plaintiff suffers severe and permanent injuries, which could have been avoided if the manufacturer had properly warned about Actos. (PRWEB) June 25, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Tennessee man who developed bladder...
Parker Waichman LLP has filed a lawsuit alleging Actos caused bladder cancer in a Louisiana woman. (PRWEB) June 23, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a woman who suffers from bladder cancer, allegedly due to Actos. The suit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical...
The national law firm of Parker Waichman LLP has filed a lawsuit alleging that Takeda’s diabetes drug, Actos, caused bladder cancer in a Louisiana man. (PRWEB) June 21, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a man who developed bladder cancer after taking Actos. Naming Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North...
Goldberg & Osborne Taking Cases After New Study Indicates that Actos Risk May Be Higher than Previously Estimated Phoenix, AZ (PRWEB) June 16, 2012 BMJ (http://www.bmj.com/content/344/bmj.e3645) recently published a study that determined that there is an increased risk of bladder cancer in those taking the commonly prescribed, type 2 diabetes drug Actos. The popular pill, manufactured by Takeda Pharmaceuticals, is widely prescribed in the United States for diabetes treatment and...
The Actos Resource Center is the Web’s largest source for information on Actos warnings, research, side effects and legal news. Visit http://www.ActosLawsuitUpdate.com. Los Angeles, CA (PRWEB) June 15, 2012 The Actos Bladder Cancer Center is alerting patients who have taken the diabetes drug Actos that newly published research has identified an explanation for the drug’s link to bladder cancer. Also, legal help is available for those affected. Anyone who has experienced symptoms of...
SAN DIEGO, June 12, 2012 /PRNewswire/ -- Scientists from numerous institutions reported at the 2012 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain sarcomas and bladder cancers are more likely to respond to treatment with ADI-PEG 20 pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase (ASS). This enzyme plays an important role in the synthesis of the amino acid arginine...
WINSTON-SALEM, N.C., June 11, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced continued clinical progress on key milestones for the ongoing Phase 1 trial of the Company's most advanced product candidate, the Neo-Urinary Conduit. "We are very pleased to report our continued progress executing on value creating milestones and believe that we are now in a position to accelerate enrollment in the Phase 1 trial of our...
